I am pleased to announce that I will be speaking @ Update on Chronic Lymphocytic Leukemia (CLL) on February 21. For more information or to register, please visit @ErmannMD @MCThompsonMD

RT @tobyeyre82: Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | New England Journal of Medicine https…

@OSUCCC_James @beatalleukemia @OhioState Congratulations!!! No one better to fill this role.

RT @tobyeyre82: Largest data set (N=64) to date outlining outcomes of VenR post cov. BTKi in @AjHematology #CLL #lymsm

RT @DrJFriedberg: As presented at ASH, now in print @JCO_ASCO: Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Na…

Honored to moderate the #CLL session today at #ASH24. Great to share the stage with my mentor and bud @DanilovLab and @niravshahmd. Congrats to @MCThompsonMD, @jeff_sharman and the other presenters on your great work.

Join me and @cllsociety on 12/17 at 3pm ET, along with [@briankoffman, @chadinabhan, @ASkarbnik, @DebbieMStephens, @NitinJainMD] as we discuss research updates on #CLL from #ASH2024 #MedTwitter #HemeOnc

RT @ASkarbnik: Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL o…

@DrLizBrem How about BV r^2?

@tvoorheesmd Great work!!!

RT @tvoorheesmd: Excited to share our multi-center experience utilizing siltuximab for CRS and ICANS! With caveats of retrospective data,…

RT @DrYukselUrun: Improving physician well-being is essential for healthcare. Organizations must reduce workload, offer confidential menta…

RT @DrJFriedberg: End Point Surrogacy in First-Line CLL: Given the clear PFS benefit in patients who achieve undetectable MRD after therapy…

RT @ASH_hematology: 🩸 ASH is launching CHAMP to support career growth and development in #hematology! Join our town hall on Nov 8 at 12 noo…

RT @DrJFriedberg: Amazing collaborations in this successful @theNCI study led by Dr. Herrera. @SWOG @eaonc @COGorg @CDNCancerTrials @ALLIA…

Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting. @TischCancer @IcahnMountSinai

RT @mshadman: Final efficacy analysis of APLINE: Zanubrutinib vs. Ibrutinib in r/r CLL Just out in @BloodJournal

@Taha_CancerDoc Agree. I tend to consider using them in the 2nd line.

MOLTO for TN #RT. Atezo + Ven + Obin. N=28, ORR - 67.9%, CR in 8 pts. OS 12 mos 64.3%. Worse outcomes assoc w/ prior CLL TRMT (29% untreated) + prior BTKi (39%). Active reg, was hoping for more CR, pt. selection may have led to improved outcomes observed.

@Taha_CancerDoc @niravshahmd @SocietyofHemOnc Sad to have missed this. 2 ?s 1) do we consolidate w/ CART or Allo if of is in CR (I would say Allo based on standard teaching). 2) if we do CART, and are able to get someone into a CR, do we proceed with Allo (Clonally related I would discuss w/ pt) More work to be done!